Results of Xarelto’s Clinical Trial Revealed

.

Results of Xarelto’s Clinical Trial Revealed

The results of clinical trials of Xarelto, a blood clot preventer drug, have been revealed. It has been informed that the drug has done far better in clinical trials as compared to the other medication which claims to prevent blood clots.

The drug Xarelto, which also has chemical name rivaroxaban, is a creation of Johnson & Johnson. During the clinical trial, about 5,000 patients were prescribed with the drug. The drug is not only effective in preventing blood clots, but is also safe to prescribe.

The manufacturer of the drug is of the view that in the coming time the drug might gain global recognition. Blood clots can cause serious health problems. They have the tendency of travelling to major organs like lung.

The clinical trial of the drug was led by Dr. Harry Buller. The results of the clinical trial were presented at American College of Cardiology during annual scientific sessions. While presenting the results, Dr. Harry said: “Rivaroxaban is just as good as standard treatment for pulmonary embolism -- these data are pretty convincing -- and this is an oral-only approach, which makes it very simple”.

While presenting the results, the results of other blood clotting preventers were also highlighted. Dr. Harry informed that about 1.1% of the patients taking Xarelto experienced major bleed as compared to 2.2% of the patients taking heparin and warfarin, blood clot preventer.

It has been informed that every year about 600,000 people succumbs to death in America because of blood clots. By introducing Xarelto for the clinical use, a large number of people could be saved from falling into the traps of death because of blood clots. Besides, Johnson & Johnson would also be able to add additional revenue of $500 million through the sales of Xarelto.


Latest News

Apigee Becomes the Second Tech Company for Silicon Valley to go Public this Year
Massive Crane Begins its First lift Helping to Build the Tappan Zee Bridge
Shares of Facebook Drop as the Social Networking Company Fails to Match Expectat
First Quarter Profits of Discover Financial Services Drops but Surpasses Analyst
Amgen Inc. Announced First Quarter Earnings that Beat Analysts’ Expectations and
Magnificent, Perfect100-carat Diamond Sells for $22Millon in Sotheby’s Jewelry A
Kraft Revamping Its Iconic Macaroni and Cheese Meal by Removing Synthetic Colour
San Juan Capistrano’s Tiered Rates for Water-Use Thrown Out by Appeals Court
Morgan Stanley Announces Better than Expected First Quarter Profits
Bombardier Aerospace secures contract from Air Niugini
Blue Cross and Blue Shield of Alabama and Alfa Insurance Are Expanding their Par
Diners Club